Norroy Bioscience has received clearance from China’s National Medical Products Administration to begin a pivotal Phase 3 trial of 177Lu-NYM032, an investigational PSMA-targeted radioligand therapy for patients with progressive metastatic castration-resistant prostate cancer. The randomized, open-label multicenter study is being led by Peking Union Medical College Hospital and will compare 177Lu-NYM032 plus best supportive or standard care with best supportive or standard care alone. Public trial-registration information lists a planned enrollment of approximately 600 patients and overall survival as the primary efficacy objective.
The trial moves another China-developed radiopharmaceutical into late-stage competition within one of oncology’s fastest-growing therapeutic classes. PSMA-directed radioligand therapy has already been commercially validated through products such as Novartis’ Pluvicto, but demand for additional agents remains high because treatment availability, isotope supply, manufacturing capacity, sequencing and efficacy in different prostate-cancer populations continue to evolve. Norroy is attempting to build both the therapeutic and diagnostic sides of that model around the same NYM032 molecular precursor.
How will the Phase 3 177Lu-NYM032 study test overall survival?
The study is designed for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer, a stage in which disease continues advancing despite treatment that suppresses androgen signaling. Patients randomized to the experimental arm will receive 177Lu-NYM032 in addition to best supportive or standard care, while the control group receives best supportive or standard care without the investigational radioligand. Overall survival will provide the pivotal test of whether targeted radioactive delivery extends life rather than merely shrinking tumors or changing prostate-specific antigen levels.
Registry data indicate a planned enrollment of roughly 600 participants and a development timeline extending through 2029. An open-label design is practical because administration of a radiopharmaceutical cannot easily be disguised from clinicians or patients, but overall survival provides an objective endpoint less vulnerable to interpretation bias than subjective response measures. Secondary endpoints are expected to provide additional information about disease progression and treatment safety as follow-up matures.
What is PSMA and why is it useful for both imaging and treatment?
Prostate-specific membrane antigen is a cell-surface protein frequently expressed at high levels in prostate-cancer cells, particularly in advanced disease. Radiopharmaceutical developers can attach different radioactive isotopes to molecules that bind PSMA, using one isotope for diagnostic imaging and another for therapeutic radiation delivery. This creates a theranostic model in which physicians can first visualize whether a patient’s tumors express enough target and then deliver treatment to many of the same lesions using a chemically related therapeutic compound.
Norroy’s program pairs diagnostic 68Ga-NYM032 with therapeutic 177Lu-NYM032. The company says the two products derive from the same precursor structure, allowing the diagnostic agent to help identify PSMA-positive disease while the lutetium-177 compound delivers beta radiation directly to target-expressing tumors. Both parts of the pair have received U.S. FDA IND clearance, although neither should be described as FDA approved.
What has Norroy shown with 177Lu-NYM032 before Phase 3?
The earlier Phase 1/2 program enrolled patients with progressive PSMA-positive metastatic castration-resistant prostate cancer who had previously received androgen-receptor-targeted treatment and, in many cases, taxane chemotherapy. Initial dose-escalation work evaluated activity levels from 1.9 GBq through 7.4 GBq, with patients receiving repeated treatment cycles at approximately six-week intervals. Eleven patients participated in the published Phase 1 dose-escalation dataset, while the broader registered Phase 1/2 study has an actual enrollment of 30 patients.
Norroy characterizes the early results as showing promising antitumor activity and a favorable safety profile and plans to disclose further Phase 1/2 data in a top-rated oral presentation at the 2026 European Association of Nuclear Medicine congress. That detailed presentation will be important because the company’s September announcement does not provide response rates, PSA reductions, progression-free survival or the complete adverse-event dataset supporting the decision to move directly into a large pivotal trial.
How does NYM032 fit into the expanding radioligand therapy market?
Radioligand therapy occupies an unusual intersection between pharmaceutical development and nuclear medicine infrastructure. The medicine itself must selectively bind the cancer target, but successful commercialization also requires reliable isotope sourcing, specialized manufacturing, radiation handling, imaging capacity and treatment centers capable of administering radioactive therapies. Norroy says it is building manufacturing facilities, isotope supply relationships and distribution capabilities alongside its drug pipeline, recognizing that clinical efficacy alone is insufficient for a radiopharmaceutical business.
Competition is likely to intensify as large pharmaceutical companies and specialist biotechnology developers pursue PSMA and additional oncology targets. New entrants therefore need to distinguish themselves through efficacy, safety, patient selection, manufacturing efficiency or the ability to reach markets where existing radioligand supply remains constrained. A successful Chinese Phase 3 program could give Norroy a substantial domestic opportunity while also supporting broader global development.
Why is the diagnostic partner 68Ga-NYM032 strategically important?
A targeted radioligand works only when sufficient target is present in the patient’s tumors. Using a related PET imaging agent allows physicians to visualize target expression across metastatic lesions before exposing a patient to therapeutic radiation. Norroy has already dosed the first patient in a Phase 3 study of 68Ga-NYM032 and is developing the diagnostic and therapeutic agents as an integrated pair.
The value of the pair extends beyond patient eligibility. Diagnostic imaging can potentially help researchers understand lesion distribution, compare uptake across disease sites and investigate whether pre-treatment imaging predicts therapeutic response. If both products eventually reach commercialization, Norroy could participate in multiple steps of the treatment pathway rather than selling only the therapeutic isotope.
What could determine whether 177Lu-NYM032 becomes commercially relevant?
Overall survival is the decisive clinical test, but comparison with an increasingly sophisticated standard of care will also matter. By the time the study matures, treatment options for metastatic castration-resistant prostate cancer may have changed further, potentially affecting how regulators and oncologists interpret a control group based on best supportive or standard care. Manufacturing reliability and isotope availability will also determine whether positive clinical results can translate into real patient access.
The Phase 3 launch nevertheless represents an important transition for Norroy. A company founded only in 2021 is moving an internally developed PSMA radioligand into a roughly 600-patient pivotal study while simultaneously building a matched diagnostic program. The remaining risk is substantial, but NYM032 has moved from a small dose-escalation experiment into a trial designed to answer the question that ultimately matters most in advanced prostate cancer: whether the treatment helps patients live longer.
